NOTE
8 — NET LOSS PER SHARE
The
computation of net loss per share and weighted-average shares of Common Stock outstanding for the periods presented are as follows:
SCHEDULE
OF EARNING PER SHARE AND WEIGHTED AVERAGE SHARES
| | |
Three months ended June 30, | |
| | |
2026 | | |
2025 | |
| Net loss attributable to common stockholders | |
$ | (1,342,740 | ) | |
$ | (1,005,824 | ) |
| Basic and diluted weighted-average common shares outstanding | |
| 12,144,768 | | |
| 11,873,799 | |
| Basic and diluted | |
$ | (0.11 | ) | |
$ | (0.08 | ) |
| | |
Nine months ended June 30, | |
| | |
2026 | | |
2025 | |
| Net loss attributable to common stockholders | |
$ | (3,668,941 | ) | |
$ | (1,718,204 | ) |
| Basic and diluted weighted-average common shares outstanding | |
| 12,135,724 | | |
| 10,645,448 | |
| Basic and diluted | |
$ | (0.30 | ) | |
$ | (0.16 | ) |
There
were no preferred or other dividends declared for the three and nine months ended June 30, 2026. The below table includes the total securities
potentially dilutive for the three and nine months ended June 30, 2026 and 2025, which have been excluded from the computation of diluted
(loss) per share.
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| | |
Three months ended June 30, | |
| | |
2026 | | |
2025 | |
| Warrants Outstanding | |
| 72,450 | | |
| - | |
| | |
Nine months ended June 30, | |
| | |
2026 | | |
2025 | |
| Warrants Outstanding | |
| 72,450 | | |
| - | |
Although
the Underwriters’ Warrants contain cashless exercise provisions, the impact of such provisions was not considered in diluted net
loss per share as the Company incurred a net loss during the period and all potential shares of Common Stock were anti-dilutive.
|